Published in J Clin Oncol on May 01, 1992
The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br J Cancer (2002) 0.99
Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen. Br J Cancer (1995) 0.98
New therapeutic possibilities in primary invasive breast cancer. Ann Surg (1993) 0.97
Prospective evaluation of prognostic factors in operable breast cancer. Br J Cancer (1996) 0.83
Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index. Support Care Cancer (2009) 0.80
Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol (1992) 2.00
Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol (1992) 1.14
Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst (1993) 4.45
Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst (1994) 4.28
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat (1992) 3.63
Aberrant subcellular localization of BRCA1 in breast cancer. Science (1995) 3.61
The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer (1980) 3.34
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst (1999) 2.58
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A (1998) 2.55
Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol (1999) 2.32
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res (1985) 2.13
Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol (1987) 2.12
Forkhead homologue in rhabdomyosarcoma functions as a bifunctional nuclear receptor-interacting protein with both coactivator and corepressor functions. J Biol Chem (2001) 2.07
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst (1998) 2.06
ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer (2000) 2.05
Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol (1992) 2.05
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol (1999) 2.00
Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol (1999) 1.89
The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer. EMBO J (1994) 1.87
Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat (1998) 1.85
Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol (1984) 1.84
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol (1995) 1.81
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst (1999) 1.75
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med (1989) 1.70
Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol (1994) 1.67
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol (2005) 1.63
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet (1996) 1.58
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res (1988) 1.57
Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J Biol Chem (1999) 1.57
Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest (1989) 1.56
Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol (1999) 1.55
HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol (1992) 1.55
Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat (1987) 1.54
The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res (1993) 1.54
Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science (1983) 1.52
Multiple estrogen receptor assays in human breast cancer. Cancer Res (1983) 1.52
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst (2000) 1.50
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol (2011) 1.45
Influence of patient characteristics, socioeconomic factors, geography, and systemic risk on the use of breast-sparing treatment in women enrolled in adjuvant breast cancer studies: an analysis of two intergroup trials. J Clin Oncol (1996) 1.43
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol (1998) 1.42
Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res (1983) 1.37
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat (1993) 1.36
Oestrogen receptors and breast cancer. BMJ (1997) 1.35
Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res (2001) 1.34
Hormone responsive human breast cancer in long-term tissue culture: effect of insulin. Proc Natl Acad Sci U S A (1976) 1.32
Epidermal growth factor stimulation of human breast cancer cells in culture. Cancer Res (1980) 1.29
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res (1996) 1.26
Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat (1994) 1.24
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study. J Clin Oncol (1997) 1.23
Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res (1989) 1.22
Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: ten-year analysis--an intergroup study. J Clin Oncol (1998) 1.21
bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer (1998) 1.21
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res (1998) 1.20
Hormone receptors in primary and advanced breast cancer. Clin Endocrinol Metab (1980) 1.19
Heterogeneity in hormone receptor status in primary and metastatic breast cancer. Semin Oncol (1985) 1.19
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res (1997) 1.17
Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation. Mol Endocrinol (2000) 1.16
Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res (1984) 1.16
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res (2000) 1.16
Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat (1994) 1.11
Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst (1997) 1.10
Correlation among insulin binding, degradation, and biological activity in human breast cancer cells in long-term tissue culture. Cancer Res (1978) 1.09
Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst (1995) 1.08
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol (1994) 1.07
Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat (1997) 1.06
Histologic progression in non-Hodgkin's lymphoma. Blood (1982) 1.06
Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study). Clin Cancer Res (1998) 1.05
An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer (1983) 1.05
Combined chemo-hormonal therapy in breast cancer: a hypothesis. Breast Cancer Res Treat (1981) 1.03
Systemic mirnas as potential biomarkers for malignancy. Int J Cancer (2012) 1.02
DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat (2010) 1.02
Prognostic factors in breast cancer. Semin Oncol (1992) 1.02
Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat (1995) 1.01
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol (1998) 1.01
Perturbation by insulin of human breast cancer cell cycle kinetics. Cancer Res (1984) 0.98
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Endocr Relat Cancer (2005) 0.97
Heat shock proteins and drug resistance. Breast Cancer Res Treat (1994) 0.96
High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer. Br J Cancer (2001) 0.96
In vitro model systems for the study of hormone-dependent human breast cancer. N Engl J Med (1977) 0.96
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol (1998) 0.95
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Res Treat (2003) 0.95
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer (2003) 0.94
The use of steroïd hormone receptors in the treatment of human breast cancer: a review. Bull Cancer (1979) 0.94
Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol (1998) 0.94
HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer. Clin Cancer Res (2000) 0.94
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat (2012) 0.94
Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. Cancer Res (1997) 0.94
Steroid hormone receptors in the management of human breast cancer. Ann Clin Res (1980) 0.94
Prognostic factors: rationale and methods of analysis and integration. Breast Cancer Res Treat (1994) 0.93
Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status. Endocrinology (1990) 0.93
Antagonism between epidermal growth factor and phorbol ester tumor promoters in human breast cancer cells. J Clin Invest (1981) 0.93
Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol (1988) 0.93
Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients. J Clin Oncol (1992) 0.92
Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer. Cancer Chemother Pharmacol (1982) 0.91
Tumor and serum tamoxifen concentrations in the athymic nude mouse. Cancer Chemother Pharmacol (1989) 0.91
Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res (2001) 0.91
Modern approaches to the treatment of breast cancer. Blood (1980) 0.90
Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. Cell Growth Differ (1994) 0.90
Response: Location of BRCA1 in Human Breast and Ovarian Cancer Cells. Science (1996) 0.90
Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis. Cancer Res (1988) 0.90